<DOC>
	<DOCNO>NCT02210858</DOCNO>
	<brief_summary>This phase I/II trial study side effect well tipifarnib work treat patient chronic myeloid leukemia , chronic myelomonocytic leukemia , undifferentiated myeloproliferative disorder . Tipifarnib may stop growth cancer cell block enzymes need cell growth .</brief_summary>
	<brief_title>Tipifarnib Treating Patients With Chronic Myeloid Leukemia , Chronic Myelomonocytic Leukemia , Undifferentiated Myeloproliferative Disorders</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To describe toxicity R115777 ( tipifarnib ) adult patient myeloproliferative disorder . II . To assess hematologic response , include change 1 ) white blood cell count 2 ) erythroid response . SECONDARY OBJECTIVES : I . To assess bone marrow cytogenetic response R115777 . II . To analyze presence neuroblastoma ( N ) /Kirsten rat sarcoma viral oncogene homolog ( K-Ras ) mutation patient bone marrow sample . III . To analyze effect R115777 Ras /DnaJ ( Hsp40 ) homolog , subfamily A , member 1 ( HDJ-2 ) farnesylation patient bone marrow/peripheral blood mononuclear cell . IV . To analyze effect R115777 mitogen-activated protein ( MAP ) kinase activation patient bone marrow mononuclear cell . V. To perform colony form unit granulocyte-macrophage ( CFU-GM ) cytotoxicity assay use patient ' hematopoietic cell R115777 . OUTLINE : Patients receive tipifarnib orally ( PO ) twice daily ( BID ) day 1-21 . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . Patients achieve good hematologic response may continue treatment discretion treat physician .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic , Atypical , BCR-ABL Negative</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>Patients diagnosis ( &gt; 3 month prior enrollment ) : Chronic myeloid leukemia ( CML ) ( Philadelphia chromosome positive polymerase chain reaction [ PCR ] positive breakpoint cluster region [ BCR ] Abelson murine leukemia viral oncogene homolog 1 [ ABL ] ) chronic phase : Persistent progressive disease maximum tolerate interferon therapy , STI571 ( eligible able receive drug ) , evidence increase white blood cell ( WBC ) count , peripheral blood myeloid immaturity and/or progressive anemia , and/or persistence relapse abnormal cytogenetic and/or molecular finding Interferon STI571 intolerant CML ( Philadelphia chromosome positive PCR positive BCRABL ) accelerate phase ( &lt; 20 % blast peripheral blood bone marrow ) persistent progressive disease STI571 ( eligible able receive drug ) CML patient eligible receive interferon STI571 allergic drug refuse use Chronic myelomonocytic leukemia ( CMML ) Proliferativetype ( WBC &gt; 12,000/ml ) Less 5 % blast peripheral blood &lt; 20 % blast bone marrow Undifferentiated myeloproliferative disorder ( UMPD ) Atypical ( i.e . Philadelphia chromosomenegative ) CML Four week must elapse since use previous pharmacotherapy include interferon , hematopoietic growth factor , cytotoxic chemotherapy ( 6 week prior mitomycin nitrosoureas ) ; hydroxyurea may use manage elevate cell count patient time begin investigational therapy Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Patients capable swallow capsule Total bilirubin &gt; 1.5 X upper limit normal ( ULN ) analysis perform ; example , Stanford University Hospital , ULN total bilirubin 1.3 Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) &gt; 2 X ULN ; example , Stanford University Hospital , ULN ALT 35 , ULN AST 41 Serum creatinine &lt; 2.0 Life expectancy &gt; 4 month Written inform consent must obtain Blast crisis phase CML atypical CML/ undifferentiated myeloproliferative disorder Patients &gt; 20 % blast peripheral blood bone marrow exclude Prior allogeneic bone marrow transplantation Patients severe disease CML , CMML , UMPD expect prevent compliance protocol Patients septicemia severe infection Pregnant breastfeed female Women reproductive age use contraception study Patients may receive androgen study Requirement ongoing therapy corticosteroid ( &gt; 10 mg/d prednisone equivalent steroid dosage ) premedication transfusion Patients iron deficiency ; marrow aspirate available , transferrin saturation must &gt; 20 % serum ferritin &gt; 50 ng/mL ; exclusion criterion remove iron deficiency state correct enrollment Patients contribute cause anemia autoimmune hereditary hemolytic disorder , gastrointestinal ( GI ) blood loss , B12 folate deficiency , hypothyroidism ; patient require platelet transfusion , thrombocytopeniarelated bleeding Inability return followup visits/studies assess toxicity response therapy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>